A randomized clinical trial of MK-0777 for the treatment of cognitive impairments in people with schizophrenia

Robert W. Buchanan, Richard S.E. Keefe, Jeffrey A. Lieberman, Deanna M. Barch, John G. Csernansky, Donald C. Goff, James M. Gold, Michael F. Green, L. Fredrik Jarskog, Daniel C. Javitt, David Kimhy, Michael S. Kraus, Joseph Patrick McEvoy, Raquelle I. Mesholam-Gately, Larry J. Seidman, M. Patricia Ball, Robert P. McMahon, Robert S. Kern, James Robinson, Stephen R. Marder

Research output: Contribution to journalArticle

108 Citations (Scopus)

Abstract

Background In a previous pilot study, MK-0777a γ-aminobutyric acid (GABA)A α2/α3 partial agonistwas reported to improve delayed memory and cognitive measures of prefrontal cortical function in people with schizophrenia. The current study was designed to further examine the efficacy and safety of MK-0777 for the treatment of cognitive impairments in schizophrenia. Methods Sixty people with DSM-IV schizophrenia entered a 4-week, multi-center, double-blind, placebo-controlled, randomized clinical trial. Participants were randomized to: MK-0777 3 mg b.i.d. (n = 18); MK-0777 8 mg b.i.d. (n = 21); or placebo (n = 21). Participants were clinically stable. The Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) Consensus Cognitive Battery, AX-Continuous Performance Test, and N-Back were used to assess cognition. The University of California San Diego (UCSD) Performance Based Skills Assessment-2 and the Schizophrenia Cognition Rating Scale assessed functional capacity and served as functional outcome coprimary measures. Results There were no significant group differences on the primary outcome measure, the MATRICS Consensus Cognitive Battery composite score. Secondary analyses suggested that participants randomized to placebo performed significantly better on visual memory and reasoning/problem-solving tests than participants assigned to either MK-0777 dose. There were no significant group differences on the AX-Continuous Performance Test or N-Back d prime scores or UCSD Performance-Based Skills Assessment2 and Schizophrenia Cognition Rating Scale total scores. In general, MK-0777 was well-tolerated with minimal side effects. Conclusions The study results suggest that MK-0777 has little benefit for cognitive impairments in people with schizophrenia. The GABAA receptor remains a promising target, but a more potent partial agonist with greater intrinsic activity at the GABAA α2 site might be needed for cognitive enhancement in schizophrenia.

Original languageEnglish (US)
Pages (from-to)442-449
Number of pages8
JournalBiological Psychiatry
Volume69
Issue number5
DOIs
StatePublished - Mar 1 2011
Externally publishedYes

Fingerprint

Schizophrenia
Randomized Controlled Trials
Cognition
Therapeutics
Placebos
Consensus
Outcome Assessment (Health Care)
Repression (Psychology)
Aminobutyrates
Cognitive Dysfunction
7-(1,1-dimethylethyl)-6-(2-ethyl-2H-1,2,4-triazol-3-ylmethoxy)-3-(2-fluorophenyl)-1,2,4-triazolo(4,3-b)pyridazine
GABA-A Receptors
Research
varespladib methyl
Diagnostic and Statistical Manual of Mental Disorders
gamma-Aminobutyric Acid
Safety

Keywords

  • Clinical trial
  • cognition
  • functional capacity
  • schizophrenia
  • symptoms
  • γ-amino-butyric acid

ASJC Scopus subject areas

  • Biological Psychiatry

Cite this

Buchanan, R. W., Keefe, R. S. E., Lieberman, J. A., Barch, D. M., Csernansky, J. G., Goff, D. C., ... Marder, S. R. (2011). A randomized clinical trial of MK-0777 for the treatment of cognitive impairments in people with schizophrenia. Biological Psychiatry, 69(5), 442-449. https://doi.org/10.1016/j.biopsych.2010.09.052

A randomized clinical trial of MK-0777 for the treatment of cognitive impairments in people with schizophrenia. / Buchanan, Robert W.; Keefe, Richard S.E.; Lieberman, Jeffrey A.; Barch, Deanna M.; Csernansky, John G.; Goff, Donald C.; Gold, James M.; Green, Michael F.; Jarskog, L. Fredrik; Javitt, Daniel C.; Kimhy, David; Kraus, Michael S.; McEvoy, Joseph Patrick; Mesholam-Gately, Raquelle I.; Seidman, Larry J.; Ball, M. Patricia; McMahon, Robert P.; Kern, Robert S.; Robinson, James; Marder, Stephen R.

In: Biological Psychiatry, Vol. 69, No. 5, 01.03.2011, p. 442-449.

Research output: Contribution to journalArticle

Buchanan, RW, Keefe, RSE, Lieberman, JA, Barch, DM, Csernansky, JG, Goff, DC, Gold, JM, Green, MF, Jarskog, LF, Javitt, DC, Kimhy, D, Kraus, MS, McEvoy, JP, Mesholam-Gately, RI, Seidman, LJ, Ball, MP, McMahon, RP, Kern, RS, Robinson, J & Marder, SR 2011, 'A randomized clinical trial of MK-0777 for the treatment of cognitive impairments in people with schizophrenia', Biological Psychiatry, vol. 69, no. 5, pp. 442-449. https://doi.org/10.1016/j.biopsych.2010.09.052
Buchanan, Robert W. ; Keefe, Richard S.E. ; Lieberman, Jeffrey A. ; Barch, Deanna M. ; Csernansky, John G. ; Goff, Donald C. ; Gold, James M. ; Green, Michael F. ; Jarskog, L. Fredrik ; Javitt, Daniel C. ; Kimhy, David ; Kraus, Michael S. ; McEvoy, Joseph Patrick ; Mesholam-Gately, Raquelle I. ; Seidman, Larry J. ; Ball, M. Patricia ; McMahon, Robert P. ; Kern, Robert S. ; Robinson, James ; Marder, Stephen R. / A randomized clinical trial of MK-0777 for the treatment of cognitive impairments in people with schizophrenia. In: Biological Psychiatry. 2011 ; Vol. 69, No. 5. pp. 442-449.
@article{ad5fb5a2c2674f3b9c23dccf3f206d6e,
title = "A randomized clinical trial of MK-0777 for the treatment of cognitive impairments in people with schizophrenia",
abstract = "Background In a previous pilot study, MK-0777a γ-aminobutyric acid (GABA)A α2/α3 partial agonistwas reported to improve delayed memory and cognitive measures of prefrontal cortical function in people with schizophrenia. The current study was designed to further examine the efficacy and safety of MK-0777 for the treatment of cognitive impairments in schizophrenia. Methods Sixty people with DSM-IV schizophrenia entered a 4-week, multi-center, double-blind, placebo-controlled, randomized clinical trial. Participants were randomized to: MK-0777 3 mg b.i.d. (n = 18); MK-0777 8 mg b.i.d. (n = 21); or placebo (n = 21). Participants were clinically stable. The Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) Consensus Cognitive Battery, AX-Continuous Performance Test, and N-Back were used to assess cognition. The University of California San Diego (UCSD) Performance Based Skills Assessment-2 and the Schizophrenia Cognition Rating Scale assessed functional capacity and served as functional outcome coprimary measures. Results There were no significant group differences on the primary outcome measure, the MATRICS Consensus Cognitive Battery composite score. Secondary analyses suggested that participants randomized to placebo performed significantly better on visual memory and reasoning/problem-solving tests than participants assigned to either MK-0777 dose. There were no significant group differences on the AX-Continuous Performance Test or N-Back d prime scores or UCSD Performance-Based Skills Assessment2 and Schizophrenia Cognition Rating Scale total scores. In general, MK-0777 was well-tolerated with minimal side effects. Conclusions The study results suggest that MK-0777 has little benefit for cognitive impairments in people with schizophrenia. The GABAA receptor remains a promising target, but a more potent partial agonist with greater intrinsic activity at the GABAA α2 site might be needed for cognitive enhancement in schizophrenia.",
keywords = "Clinical trial, cognition, functional capacity, schizophrenia, symptoms, γ-amino-butyric acid",
author = "Buchanan, {Robert W.} and Keefe, {Richard S.E.} and Lieberman, {Jeffrey A.} and Barch, {Deanna M.} and Csernansky, {John G.} and Goff, {Donald C.} and Gold, {James M.} and Green, {Michael F.} and Jarskog, {L. Fredrik} and Javitt, {Daniel C.} and David Kimhy and Kraus, {Michael S.} and McEvoy, {Joseph Patrick} and Mesholam-Gately, {Raquelle I.} and Seidman, {Larry J.} and Ball, {M. Patricia} and McMahon, {Robert P.} and Kern, {Robert S.} and James Robinson and Marder, {Stephen R.}",
year = "2011",
month = "3",
day = "1",
doi = "10.1016/j.biopsych.2010.09.052",
language = "English (US)",
volume = "69",
pages = "442--449",
journal = "Biological Psychiatry",
issn = "0006-3223",
publisher = "Elsevier USA",
number = "5",

}

TY - JOUR

T1 - A randomized clinical trial of MK-0777 for the treatment of cognitive impairments in people with schizophrenia

AU - Buchanan, Robert W.

AU - Keefe, Richard S.E.

AU - Lieberman, Jeffrey A.

AU - Barch, Deanna M.

AU - Csernansky, John G.

AU - Goff, Donald C.

AU - Gold, James M.

AU - Green, Michael F.

AU - Jarskog, L. Fredrik

AU - Javitt, Daniel C.

AU - Kimhy, David

AU - Kraus, Michael S.

AU - McEvoy, Joseph Patrick

AU - Mesholam-Gately, Raquelle I.

AU - Seidman, Larry J.

AU - Ball, M. Patricia

AU - McMahon, Robert P.

AU - Kern, Robert S.

AU - Robinson, James

AU - Marder, Stephen R.

PY - 2011/3/1

Y1 - 2011/3/1

N2 - Background In a previous pilot study, MK-0777a γ-aminobutyric acid (GABA)A α2/α3 partial agonistwas reported to improve delayed memory and cognitive measures of prefrontal cortical function in people with schizophrenia. The current study was designed to further examine the efficacy and safety of MK-0777 for the treatment of cognitive impairments in schizophrenia. Methods Sixty people with DSM-IV schizophrenia entered a 4-week, multi-center, double-blind, placebo-controlled, randomized clinical trial. Participants were randomized to: MK-0777 3 mg b.i.d. (n = 18); MK-0777 8 mg b.i.d. (n = 21); or placebo (n = 21). Participants were clinically stable. The Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) Consensus Cognitive Battery, AX-Continuous Performance Test, and N-Back were used to assess cognition. The University of California San Diego (UCSD) Performance Based Skills Assessment-2 and the Schizophrenia Cognition Rating Scale assessed functional capacity and served as functional outcome coprimary measures. Results There were no significant group differences on the primary outcome measure, the MATRICS Consensus Cognitive Battery composite score. Secondary analyses suggested that participants randomized to placebo performed significantly better on visual memory and reasoning/problem-solving tests than participants assigned to either MK-0777 dose. There were no significant group differences on the AX-Continuous Performance Test or N-Back d prime scores or UCSD Performance-Based Skills Assessment2 and Schizophrenia Cognition Rating Scale total scores. In general, MK-0777 was well-tolerated with minimal side effects. Conclusions The study results suggest that MK-0777 has little benefit for cognitive impairments in people with schizophrenia. The GABAA receptor remains a promising target, but a more potent partial agonist with greater intrinsic activity at the GABAA α2 site might be needed for cognitive enhancement in schizophrenia.

AB - Background In a previous pilot study, MK-0777a γ-aminobutyric acid (GABA)A α2/α3 partial agonistwas reported to improve delayed memory and cognitive measures of prefrontal cortical function in people with schizophrenia. The current study was designed to further examine the efficacy and safety of MK-0777 for the treatment of cognitive impairments in schizophrenia. Methods Sixty people with DSM-IV schizophrenia entered a 4-week, multi-center, double-blind, placebo-controlled, randomized clinical trial. Participants were randomized to: MK-0777 3 mg b.i.d. (n = 18); MK-0777 8 mg b.i.d. (n = 21); or placebo (n = 21). Participants were clinically stable. The Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) Consensus Cognitive Battery, AX-Continuous Performance Test, and N-Back were used to assess cognition. The University of California San Diego (UCSD) Performance Based Skills Assessment-2 and the Schizophrenia Cognition Rating Scale assessed functional capacity and served as functional outcome coprimary measures. Results There were no significant group differences on the primary outcome measure, the MATRICS Consensus Cognitive Battery composite score. Secondary analyses suggested that participants randomized to placebo performed significantly better on visual memory and reasoning/problem-solving tests than participants assigned to either MK-0777 dose. There were no significant group differences on the AX-Continuous Performance Test or N-Back d prime scores or UCSD Performance-Based Skills Assessment2 and Schizophrenia Cognition Rating Scale total scores. In general, MK-0777 was well-tolerated with minimal side effects. Conclusions The study results suggest that MK-0777 has little benefit for cognitive impairments in people with schizophrenia. The GABAA receptor remains a promising target, but a more potent partial agonist with greater intrinsic activity at the GABAA α2 site might be needed for cognitive enhancement in schizophrenia.

KW - Clinical trial

KW - cognition

KW - functional capacity

KW - schizophrenia

KW - symptoms

KW - γ-amino-butyric acid

UR - http://www.scopus.com/inward/record.url?scp=79951656529&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79951656529&partnerID=8YFLogxK

U2 - 10.1016/j.biopsych.2010.09.052

DO - 10.1016/j.biopsych.2010.09.052

M3 - Article

VL - 69

SP - 442

EP - 449

JO - Biological Psychiatry

JF - Biological Psychiatry

SN - 0006-3223

IS - 5

ER -